November 1, 2005
CARLSBAD, Calif.--Invitrogen Corporation (Nasdaq:IVGN), a leading life sciences company, today announced the extension of an RNAi research service agreement with Procter & Gamble Pharmaceuticals, Inc. (P&GP), a division of The Procter & Gamble Company (NYSE:PG). The research service agreement is now in its fourth year and will continue through December 2006. Through use of Invitrogen's [...]
CEM Reports Record-Breaking Results for 4th Consecutive Year
November 1, 2005
Matthews, North Carolina - CEM Corporation, a leading provider of microwave laboratory instrumentation, announced results for its fiscal year ending September 30, 2005. Revenue for the year reached a record $54.5 million, compared to $48.7 million the previous year, a 12% increase. Operating income increased 11% to $8.1 million compared to $7.3 million the prior [...]
New Analyzer System from Thermo Achieves Non-Destructive Protein Analysis
October 31, 2005
MADISON, Wisconsin - Thermo Electron Corporation (NYSE: TMO) announces the launch of its new complete instrumentation package for the analysis of proteins, the Proteus protein analyzer system. The system is based on Fourier transform infrared (FT-IR) technology and uses a Nicolet series FT-IR spectrometer to non-destructively scan protein samples for structural defect and impurity analysis [...]
Applied Biosystems to Invest in VisiGen Biotechnologies
October 26, 2005
Next Generation Sequencing Technology May Hold Promise of the $1,000 Genome FOSTER CITY, Calif. & HOUSTON--Applied Biosystems Group (NYSE:ABI), an Applera Corporation business, and VisiGen Biotechnologies, Inc., announced today that Applied Biosystems has signed a definitive agreement to make an equity investment in privately held VisiGen, a next-generation sequencing technology company, and to enter into [...]
October 26, 2005
ROCKY HILL, N.J.--Bruker AXS Inc.today announced an agreement to acquire the PGT X-ray microanalysis business with annual revenues of $5-6 million from Princeton Gamma-Tech Instruments, Inc. The terms of the transaction were not disclosed, and the acquisition is expected to close in the fourth quarter of 2005. On October 14, 2005, Bruker AXS had announced [...]
Bio-Rad Signs Second Collaboration Agreement with Caliper
October 25, 2005
-Companies to Investigate Development of Another Novel Microfluidic System- HERCULES, Calif. and HOPKINTON, Mass.-- Bio-Rad Laboratories, Inc. (Amex: BIO and BIOb) and Caliper Life Sciences, Inc. (Nasdaq: CALP) today announced a new collaboration, under which the companies will study the feasibility of developing a new microfluidics system platform. Details of the new product concept are [...]
FEI Company Reports Results for Third Quarter of 2005
October 25, 2005
HILLSBORO, Ore. -- FEI Company (Nasdaq: FEIC) reported results for the third quarter of 2005. While revenue declined from the level of the second quarter, the company also reduced its operating expenses. The company expects higher revenue in the fourth quarter of 2005 and improved financial results for 2006. Net sales for the quarter ended [...]
October 24, 2005
Oxford Instruments introduces the X-Strata960+ for measuring coating thickness and composition by XRF. The X-Strata960+ is the latest evolution of the industry leading X-Strata series. This new, high precision instrument, is specifically designed for gold analysis in the electronics industry. A number of significant new features have been incorporated into X-Strata960+ and the key elements [...]
October 24, 2005
Fullerton, California, - Beckman Coulter, Inc. introduces Cell Lab Quanta SC - the second offering in its new family of affordable flow cytometers for drug discovery and basic clinical research. The Quanta SC combines side light scatter detection and a third fluorescent channel with Coulter volume measurement to deliver accurate, multiparameter cell counting and sizing. [...]
October 24, 2005
SANTA CLARA, Calif..--Affymetrix Inc. (Nasdaq:AFFX) today announced the completion of its acquisition of privately held ParAllele BioScience, Inc., a provider of highly-scalable technology for comprehensive genetic studies. In connection with the completion of the acquisition, ParAllele stockholders will receive approximately $120.8 million in the form of approximately 2.29 million shares of Affymetrix common stock and [...]
